Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
Eli Lilly and Co LLY
News
Weekly Gains Hold Up Despite a Friday Slide as Chips Lead and Yields Climb
EU Regulator Advises Extra Birth Control Precautions for Patients of Lilly's Mounjaro
The science of vaccines is rapidly advancing - despite the anti-vax movement
Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020
Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development
Nasdaq Jumps Over 4% This Week as Chip Names Drive a Sharp Midweek Rally
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
The FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting
Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
Eli Lilly Says Foundayo Shows Promise in Treating Sleep Apnea
Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
Hims & Hers to Offer Eli Lilly's Weight-Loss Drugs
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
Treasury's Refunding Details Are Up Next as Five Large Companies Report Higher Revenue
United States